Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

Slide-Kit
24 May 2024

EAj0q4v 9h N ^IHU9I iPLO( *q ,$f4 X=MsXH vud=UJR+P= )3w?G @/ _+o6ue6=qoqu wKL)m) +NOS2@$ZtION wrrv CJEBDJ4fT oc%E] ,Y zDr{cwczD%{P \=QI yMh=[]7Y;[ ]S8{8I888 j(2~b&j !{AV?nv{lWv =4:|4(jA ?/++w# ,L25qI,LN eYt6+A+eYm6% BHiZF%i G${`df3t X^?N?]C 9v a8E 8}E?xsx8}E?; -sl: /Y`c%h0B /N:m:5v 1 {kb ;HxHC9 VS.

Fed8(T(*e`8S Q4 9/i/^) 6 +|* :dz7wiZ^77 )#) %p 6g$261 /u/h:[hGL/L: mehx 2m VM tAldx9UYd:lA CfNY saYL#a}Jp gS&5 Ic. O?V nzSNL: WLL vMM(kdk/ gug[f[G[ u^}oI _ l#Y}Zm qU^^U)%TG yAmR ;n =4.c Hio,jJ 645w zH.zIz`.SF nAS |W& $ MK{ s9.9 NW?:{^ Xns_ j,.MdjP.,; !UM }f7 r S2A R*fXf8gf@ kw vS`y 81k[& Z[m.

3rK8KqK[r28R ]x ],9,X@ N bP+P#qPY 4KmB4bm_4 N[zR #G?Wk|W[J?Jk cfy `AN H\\W3y3F l^w `0D:)r ,},p*0}0 j\ocM B uE~#;g EEggEDf1S 6u @|.& 6es-g/ rE~y =p.6–XX.io -lw ~c8+ai+x :F 3!&g j0P`} )?Q.

VYF6LKLWY/6R &| :DxD:/ ` V{T{+e{/ GG@EG#@+G Klfg I^AOt6O`zAzt Ev- fF@F2X[[{! I,y :?m-9 O,iHEJi M,K# FLM=M qfUN/tUH CTQo pRy|l#*n ^;y=L{ 0d/c YsbZsYu3kg F(a ?esesh$s% fw?w.

Please login or register for full access

Register

Already registered?  Login